论文部分内容阅读
目的:了解2009~2015年浙江省11家医院肺癌患者表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKI)的利用现状,分析其用药合理性。方法:抽取2009~2015年浙江省11家医院每年40天的医嘱数据,对肺癌患者使用EGFR-TKI的用药金额、用药频度(DDDs)、限定日费用(DDC)以及药物利用指数(DUI)进行统计分析。结果:埃克替尼、厄洛替尼和吉非替尼是目前最主要的3种EGFR-TKI,其中埃克替尼2013年之后才开始使用。EGFR-TKI的用药总金额总体呈上升趋势,2015年的销售总金额是2009年的4.67倍;厄洛替尼的DDDs总体呈降低趋势,吉非替尼和埃克替尼的DDDs逐年升高;DDC排序最高的是厄洛替尼,吉非替尼次之,埃克替尼最低;3种靶向药物的DUI值均在1左右。结论:浙江省11家医院EGFR-TKI的用量逐年升高,但使用相对合理。
OBJECTIVE: To investigate the status quo of EGFR-TKI in 11 patients with lung cancer from 2009 to 2015 in Zhejiang Province and to analyze its rationality. Methods: The medical prescription data of 40 hospitals in 11 hospitals in Zhejiang Province from 2009 to 2015 were collected and used to determine the dosage of EGFR-TKI, DDDs, DDC and DUI in patients with lung cancer. conduct statistical analysis. RESULTS: Icitinib, erlotinib, and gefitinib were the three major EGFR-TKIs currently in use, with imatinib being available only after 2013. The total amount of EGFR-TKI medication was generally on the rise. The total amount of sales in 2015 was 4.67 times of that in 2009. The DDDs of erlotinib generally showed a decreasing trend. The DDDs of gefitinib and icotinib increased year by year The highest DDC was erlotinib, followed by gefitinib and the lowest of icotinib. The DUI values of three kinds of targeted drugs were all around 1. Conclusion: The dosage of EGFR-TKI in 11 hospitals in Zhejiang Province has been increasing year by year, but its use is relatively reasonable.